March Biosciences
Houston
About March Biosciences
March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. The company's lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 1 trials in patients with refractory T-cell lymphoma and leukemia.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $46.8M
- Funding stage: Early Stage Venture
- Last round: Grant (Apr 2025)
- Website: march.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/march-biosciences-29422 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.